awmsg logo



pertuzumab (Perjeta®)


Reference No. 1373

Publication date:
18/11/2015


Appraisal information

pertuzumab (Perjeta®) 420 mg concentrate for solution for infusion


Company: Roche Products Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Superseded
Advice No: Not available
Ratification by Welsh Government: 17/11/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA424) NICE GUIDANCE ISSUED DECEMBER 2016 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) In the absence of a submission from the holder of the marketing authorisation, pertuzumab (Perjeta®) cannot be endorsed for use within NHS Wales in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.
Statement of Advice (SOA)
Download